KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Income from Continuing Operations data on record, last reported at 208471000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 9.07% year-over-year to 208471000.0; the TTM value through Dec 2025 reached 103442000.0, down 118.41%, while the annual FY2025 figure was 355459000.0, 163.27% down from the prior year.
  • Income from Continuing Operations reached 208471000.0 in Q4 2025 per JAZZ's latest filing, up from 718384000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 215340000.0 in Q3 2024 and bottomed at 718384000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 4077500.0, with a median of 53769500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: tumbled 641.54% in 2022, then skyrocketed 1116.53% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 32363000.0 in 2021, then crashed by 641.54% to 239984000.0 in 2022, then soared by 139.43% to 94626000.0 in 2023, then soared by 101.99% to 191131000.0 in 2024, then increased by 9.07% to 208471000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 208471000.0 in Q4 2025, 718384000.0 in Q2 2025, and 191131000.0 in Q4 2024.